Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Sickle Cell Disease

In brief

This study is designed to address the feasibility of a randomized, double masked, cross-over study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).

Key facts

Study ID
NCT03978156
Run by
Yale University
People needed
6
Starts
2019-07-26
Expected to finish
2021-01-01
Last updated by the study team
2021-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.